vs
Side-by-side financial comparison of Apellis Pharmaceuticals, Inc. (APLS) and MACH NATURAL RESOURCES LP (MNR). Click either name above to swap in a different company.
MACH NATURAL RESOURCES LP is the larger business by last-quarter revenue ($387.5M vs $199.9M, roughly 1.9× Apellis Pharmaceuticals, Inc.). MACH NATURAL RESOURCES LP runs the higher net margin — 18.9% vs -29.5%, a 48.3% gap on every dollar of revenue. On growth, MACH NATURAL RESOURCES LP posted the faster year-over-year revenue change (65.0% vs -5.9%). Over the past eight quarters, MACH NATURAL RESOURCES LP's revenue compounded faster (27.3% CAGR vs 7.7%).
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
MACH NATURAL RESOURCES LPMNREarnings & Financial Report
Mach Natural Resources LP is a US-based upstream energy enterprise focused on the exploration, development, and production of oil, natural gas, and natural gas liquids. Its core operations are located in onshore US hydrocarbon basins including the Permian Basin, prioritizing low-cost, high-yield assets to drive sustainable returns for stakeholders.
APLS vs MNR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $199.9M | $387.5M |
| Net Profit | $-59.0M | $73.1M |
| Gross Margin | — | — |
| Operating Margin | -25.6% | 26.1% |
| Net Margin | -29.5% | 18.9% |
| Revenue YoY | -5.9% | 65.0% |
| Net Profit YoY | -62.2% | 100.2% |
| EPS (diluted) | $-0.40 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $199.9M | $387.5M | ||
| Q3 25 | $458.6M | $272.6M | ||
| Q2 25 | $178.5M | $288.5M | ||
| Q1 25 | $166.8M | $226.8M | ||
| Q4 24 | $212.5M | $234.9M | ||
| Q3 24 | $196.8M | $255.5M | ||
| Q2 24 | $199.7M | $240.0M | ||
| Q1 24 | $172.3M | $239.2M |
| Q4 25 | $-59.0M | $73.1M | ||
| Q3 25 | $215.7M | $-35.7M | ||
| Q2 25 | $-42.2M | $89.7M | ||
| Q1 25 | $-92.2M | $15.9M | ||
| Q4 24 | $-36.4M | $36.5M | ||
| Q3 24 | $-57.4M | $67.4M | ||
| Q2 24 | $-37.7M | $39.5M | ||
| Q1 24 | $-66.4M | $41.7M |
| Q4 25 | -25.6% | 26.1% | ||
| Q3 25 | 48.7% | -7.0% | ||
| Q2 25 | -18.6% | 38.6% | ||
| Q1 25 | -50.0% | 22.8% | ||
| Q4 24 | -12.3% | 24.9% | ||
| Q3 24 | -24.0% | 37.1% | ||
| Q2 24 | -14.7% | 29.4% | ||
| Q1 24 | -36.0% | 28.1% |
| Q4 25 | -29.5% | 18.9% | ||
| Q3 25 | 47.0% | -13.1% | ||
| Q2 25 | -23.6% | 31.1% | ||
| Q1 25 | -55.3% | 7.0% | ||
| Q4 24 | -17.1% | 15.5% | ||
| Q3 24 | -29.2% | 26.4% | ||
| Q2 24 | -18.9% | 16.5% | ||
| Q1 24 | -38.5% | 17.4% |
| Q4 25 | $-0.40 | $0.47 | ||
| Q3 25 | $1.67 | $-0.28 | ||
| Q2 25 | $-0.33 | $0.76 | ||
| Q1 25 | $-0.74 | $0.14 | ||
| Q4 24 | $-0.30 | $0.34 | ||
| Q3 24 | $-0.46 | $0.70 | ||
| Q2 24 | $-0.30 | $0.42 | ||
| Q1 24 | $-0.54 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $466.2M | $42.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $370.1M | — |
| Total Assets | $1.1B | $3.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $466.2M | $42.6M | ||
| Q3 25 | $479.2M | $53.6M | ||
| Q2 25 | $370.0M | $13.8M | ||
| Q1 25 | $358.4M | $7.8M | ||
| Q4 24 | $411.3M | $105.8M | ||
| Q3 24 | $396.9M | $184.5M | ||
| Q2 24 | $360.1M | $144.6M | ||
| Q1 24 | $325.9M | $151.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | — | ||
| Q2 25 | $156.3M | — | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | — | ||
| Q3 24 | $237.1M | — | ||
| Q2 24 | $264.3M | — | ||
| Q1 24 | $266.7M | — |
| Q4 25 | $1.1B | $3.8B | ||
| Q3 25 | $1.1B | $3.8B | ||
| Q2 25 | $821.4M | $2.3B | ||
| Q1 25 | $807.3M | $2.2B | ||
| Q4 24 | $885.1M | $2.3B | ||
| Q3 24 | $901.9M | $2.3B | ||
| Q2 24 | $904.5M | $2.2B | ||
| Q1 24 | $831.9M | $2.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.2M | $128.7M |
| Free Cash FlowOCF − Capex | $-14.3M | — |
| FCF MarginFCF / Revenue | -7.1% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 1.76× |
| TTM Free Cash FlowTrailing 4 quarters | $45.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.2M | $128.7M | ||
| Q3 25 | $108.5M | $105.5M | ||
| Q2 25 | $4.4M | $130.1M | ||
| Q1 25 | $-53.4M | $142.5M | ||
| Q4 24 | $19.4M | $133.7M | ||
| Q3 24 | $34.1M | $110.8M | ||
| Q2 24 | $-8.3M | $116.8M | ||
| Q1 24 | $-133.0M | $144.0M |
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | 1.76× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 1.45× | ||
| Q1 25 | — | 8.97× | ||
| Q4 24 | — | 3.66× | ||
| Q3 24 | — | 1.64× | ||
| Q2 24 | — | 2.96× | ||
| Q1 24 | — | 3.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
MNR
| Oil Gas And Natural Gas Liquids Net | $331.0M | 85% |
| Natural Gas Liquids Reserves | $44.8M | 12% |
| Natural Gas Midstream | $8.6M | 2% |
| Products | $6.3M | 2% |
